Literature DB >> 15831940

Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells.

Latifa Bousarghin1, Pascale Hubert1, Elisabeth Franzen1, Nathalie Jacobs2,1, Jacques Boniver1, Philippe Delvenne1.   

Abstract

Langerhans cells (LC), the immature dendritic cells (DC) that reside in epithelial tissues are among the first immune cells to encounter human papillomavirus (HPV) and are not activated by HPV virus-like particles (VLPs) in contrast to DC. The notion that the differences in response to HPV VLPs between LC and DC are associated with different types of cell binding and intracellular trafficking has been addressed. Inhibition experiments with heparin and sodium chlorate showed that heparan sulfates are necessary for HPV 16 VLPs to bind to DC but not to LC. Electron microscopy analysis demonstrated a colocalization of HPV 16 VLPs and langerin, which is expressed only by LC. This colocalization was observed on the cell surface but also in cytoplasmic vesicles. As anti-langerin antibodies, HPV 16 VLPs were associated with a faster entry kinetics in LC, as reflected by the fact that VLPs were observed near the nuclear membrane of LC within 10 min whereas more than 60 min were needed in DC. However, no difference between LC and DC was observed for the endocytosis pathway. HPV 16 VLPs entered in both DC and LC by a clathrin-dependent-pathway and were then localized in large cytoplasmic vesicles resembling endosomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831940     DOI: 10.1099/vir.0.80559-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Authors:  Andrew W Woodham; Adam B Raff; Laura M Raff; Diane M Da Silva; Lisa Yan; Joseph G Skeate; Michael K Wong; Yvonne G Lin; W Martin Kast
Journal:  J Immunol       Date:  2014-04-09       Impact factor: 5.422

Review 2.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

3.  A major role for the minor capsid protein of human papillomavirus type 16 in immune escape.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

4.  Dendritic cell internalization of foot-and-mouth disease virus: influence of heparan sulfate binding on virus uptake and induction of the immune response.

Authors:  Lisa J Harwood; Heidi Gerber; Francisco Sobrino; Artur Summerfield; Kenneth C McCullough
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

5.  Heparan sulfate-binding foot-and-mouth disease virus enters cells via caveola-mediated endocytosis.

Authors:  Vivian O'Donnell; Michael Larocco; Barry Baxt
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

6.  Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry.

Authors:  Patrick L Hindmarsh; Laimonis A Laimins
Journal:  Virol J       Date:  2007-02-26       Impact factor: 4.099

Review 7.  Influence of dendritic cells on viral pathogenicity.

Authors:  Giulia Freer; Donatella Matteucci
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

Review 8.  Mechanisms of cell entry by human papillomaviruses: an overview.

Authors:  Caroline A J Horvath; Gaëlle A V Boulet; Virginie M Renoux; Philippe O Delvenne; John-Paul J Bogers
Journal:  Virol J       Date:  2010-01-20       Impact factor: 4.099

9.  Glycosaminoglycans are interactants of Langerin: comparison with gp120 highlights an unexpected calcium-independent binding mode.

Authors:  Eric Chabrol; Alessandra Nurisso; Antoine Daina; Emilie Vassal-Stermann; Michel Thepaut; Eric Girard; Romain R Vivès; Franck Fieschi
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells.

Authors:  Johan M J Van den Bergh; Khadija Guerti; Yannick Willemen; Eva Lion; Nathalie Cools; Herman Goossens; Alex Vorsters; Viggo F I Van Tendeloo; Sébastien Anguille; Pierre Van Damme; Evelien L J M Smits
Journal:  J Cell Mol Med       Date:  2014-06-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.